Mr. Andrew Alvis reports
ISODIOL ANNOUNCES CONVERSION OF DEBENTURES
Isodiol International Inc. has issued 8.2 million common shares in the capital of the company in payment of an aggregate of $410,000 in principal outstanding, in accordance with the terms
and conditions of its amended and restated 4 per cent senior unsecured convertible debentures.
The common shares in payment of the principal of the debentures have been issued pursuant to exemptions from the prospectus requirements of applicable securities laws.
Isodiol believes that the conversion of the debentures will provide balance sheet flexibility and will reduce annual debt servicing costs for the company.
As of the date hereof, debentures in the principal amount of $2.24-million remain outstanding and due to mature on Nov. 29, 2021.
For additional details of the debentures, please refer to the company's news releases dated Nov. 30, 2018, and April 1, 2020.
About Isodiol International Inc.
Isodiol International is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer packaged goods (CPG) and solutions. Isodiol has commercialized a 99-per-cent-plus-pure, naturally isolated CBD (cannabidiol), including microencapsulations and nanotechnology for quality consumable and topical skin care products. Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.